GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)
Close on Nov 16, 2026Market cap $1.52BP/E –Yield –
GeneDx r&d expenses
Research and development expenses are spending on new products and technology.
GeneDx's R&D Expenses for the twelve months ending Jun 30, 2026 was $83.83M, up 64.7% year over year. For fiscal 2025 it was $72.03M, up 57.5% from the year before. The highest annual figure on record is $105.16M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.03M | +57.5% |
| FY2024 | Dec 31, 2024 | $45.72M | -21.5% |
| FY2023 | Dec 31, 2023 | $58.27M | -32.4% |
| FY2022 | Dec 31, 2022 | $86.20M | -18.0% |
| FY2021 | Dec 31, 2021 | $105.16M | +44.7% |
| FY2020 | Dec 31, 2020 | $72.70M | +108.2% |
| FY2019 | Dec 31, 2019 | $34.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.66M | +30.4% |
| Q1 FY2026 | Mar 31, 2026 | $19.80M | +57.5% |
| Q4 FY2025 | Dec 31, 2025 | $24.54M | +111.8% |
| Q3 FY2025 | Sep 30, 2025 | $19.83M | +70.0% |
| Q2 FY2025 | Jun 30, 2025 | $15.08M | +38.3% |
| Q1 FY2025 | Mar 31, 2025 | $12.58M | +8.7% |
| Q4 FY2024 | Dec 31, 2024 | $11.59M | -5.4% |
| Q3 FY2024 | Sep 30, 2024 | $11.67M | -18.4% |
| Q2 FY2024 | Jun 30, 2024 | $10.90M | -36.4% |
| Q1 FY2024 | Mar 31, 2024 | $11.57M | -20.7% |
| Q4 FY2023 | Dec 31, 2023 | $12.25M | -49.7% |
| Q3 FY2023 | Sep 30, 2023 | $14.29M | +7.0% |
| Q2 FY2023 | Jun 30, 2023 | $17.14M | -36.9% |
| Q1 FY2023 | Mar 31, 2023 | $14.59M | -31.5% |
| Q4 FY2022 | Dec 31, 2022 | $24.37M | +9.5% |
| Q3 FY2022 | Sep 30, 2022 | $13.35M | -25.1% |
| Q2 FY2022 | Jun 30, 2022 | $27.17M | +127.3% |
| Q1 FY2022 | Mar 31, 2022 | $21.32M | -59.9% |
| Q4 FY2021 | Dec 31, 2021 | $22.25M | -28.6% |
| Q3 FY2021 | Sep 30, 2021 | $17.83M | -6.6% |
| Q2 FY2021 | Jun 30, 2021 | $11.95M | +27.7% |
| Q1 FY2021 | Mar 31, 2021 | $53.13M | +305.7% |
| Q4 FY2020 | Dec 31, 2020 | $31.16M | – |
| Q3 FY2020 | Sep 30, 2020 | $19.08M | – |
| Q2 FY2020 | Jun 30, 2020 | $9.36M | – |
| Q1 FY2020 | Mar 31, 2020 | $13.10M | – |
See a number that looks wrong?